Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension-Reference-Cited by-同舟云学术

Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension

Published:2013-06 Issue:12 Volume:23 Page:3650-3653
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Bauman David R.,Whitehead Alan,Contino Lisa C.,Cui Jisong,Garcia-Calvo Margarita,Gu Xin,Kevin Nancy,Ma Xiuying,Pai Lee-yuh,Shah Kashmira,Shen Xiaolan,Stribling Sloan,Zokian Hratch J.,Metzger Joe,Shevell Diane E.,Waddell Sherman T.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference21 articles.

1. The pituitary–adrenal axis and body composition

2. 11β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation

3. The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis

4. Tissue-Specific Glucocorticoid Reactivating Enzyme, 11β-Hydroxysteoid Dehydrogenase Type 1 (11β-HSD1) - A Promising Drug Target for the Treatment of Metabolic Syndrome

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JTT-654, an 11-beta hydroxysteroid dehydrogenase type 1 inhibitor, improves hypertension and diabetic kidney injury by suppressing angiotensinogen production;Journal of Pharmacological Sciences;2024-04

2. Exceptional reactivity of the bridgehead amine on bicyclo[1.1.1]pentane;Arkivoc;2023-08-23

3. Gut microbiota, hypertension and chronic kidney disease: Recent advances;Pharmacological Research;2019-06

4. 11β-Hydroxysteroid Dehydrogenases and Hypertension in the Metabolic Syndrome;Current Hypertension Reports;2017-11-14

5. Searching for novel applications of the benzohomoadamantane scaffold in medicinal chemistry: Synthesis of novel 11β-HSD1 inhibitors;Bioorganic & Medicinal Chemistry;2015-12